EPS growth is an important number as it indicates the future prospects of ArQule. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 1252.90 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money ArQule is making for it’s investors or shareholders.
ArQule trades as part of the healthcare sector and is in the biotechnology industry. The company CEO is Paolo Pucci. Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases.
Previous Intraday Performance:
The ARQL shares had a previous change of 1.37% which opened at 3.66 and closed at 3.71. It moved to an intraday high of 3.81 and a low of 3.55.
Historical Performance:
Over the last five trading days, ARQL shares returned 1.37% and in the past 30 trading days it returned -14.12%. Over three months, it changed -40.26%. In one year it has changed 154.11% and within that year its 52-week high was 7.21 and its 52-week low was 1.27. ARQL stock is 192.13% above its 52 Week Low.
Our calculations result in a 200 day moving average of 4.19 and a 50 day moving average of 4.30. Right now, ARQL stock is trading -11.53% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
Liquidity:
The company has a market cap of $404.4m with 109.0m shares outstanding and a float of 107.2m shares. Trading volume was 2,359,313 shares and has experienced an average volume of 1,138,221 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for ArQule was -0.39 which ended on 31st of December 2017. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.06.
Below was the last reported quarterly earnings per share:
09-30-2018: -0.05
06-30-2018: 0.05
03-31-2018: -0.07
12-31-2017: -0.09
Base on our calculations, the intrinsic value per share is 0.80, which means it might overvalued by -365.57%
Indicators Also to Watch:
Based on the latest filings, there is 20.40% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.63
SeekingAlpha: Natural gas jumps as cold air descends on U.S. Midwest
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -31.70%, return on assets is -21.00%, profit margin is -60.83%, price-to-sales is 17.48 and price-to-book is 4.64.
Company Score Card:
Results are out of six:
1 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: ARQL, ArQule, Biotechnology, Healthcare
